CDER Approvals In January Came Early And Often
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA started 2012 with a bang: five novel approvals in January, including two of the fastest approval times in modern agency history (and the fastest therapeutic approval outside of oncology), plus two big decisions on anti-diabetics.
You may also be interested in...
Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
Technical Difficulties Prevented Priority Review Of GSK Melanoma Drugs
GlaxoSmithKline withdrew priority review requests for its high-profile melanoma drugs Mekinist and Tafinlar as extensive problems with both the quality of the NDA data and the statistical analysis software in the electronic submissions emerged. Statistical reviewers called out sponsor for inadequate response to problems, wasting time.